Adherex Announces Abstracts for 2007 ASCO Meeting

Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the following three abstracts will be presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday, June 3, 2007 from 8:00 AM to 12:00 PM:

“An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors.” Poster Number H14, Abstract No. 3567 by Q. Chu, D.J. Jonker, J. Knox, G. Batist, P. Venner, K.N. Chi, L. Wood, J. Reeves, P. Kavan, E. Arrowsmith, H.A. Burris III, R.K. Malik and W.P. Peters.

“Elucidating the mechanisms responsible for the previous failure of phase III clinical trials with eniluracil (EU) and development of a novel scheduling approach to optimize the efficacy of EU/5-fluorouracil (5-FU) combination therapy.” Poster Number B13, Abstract No. 2557 by V. Guarcello, J. Fourie, M.J. Lawton, W.P. Peters, M.J. Heslin and R.B. Diasio.

“A phase I study evaluating a novel schedule of oral eniluracil (EU) combined with escalating doses of oral 5-fluorouracil (5- FU).” Poster Number C2, Abstract No. 2560 by J.R. Infante, S.F. Jones, M.J. Lawton, P. Wing, R.K. Malik, W.P. Peters and H.A. Burris III.